T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial

T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial

283056

T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial

ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that develops around the joints and tendons, new clinical trial data show. The findings were presented at the Connective Tissue Oncology Society (CTOS) annual meeting by trial investigator Brian Van Tine, MD, PhD, of the Washington University School of Medicine. The oral presentation was titled, “Durable Responses…

You must be logged in to read/download the full post.